<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/379h–2" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/379h–2/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/379h–2/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_379h_2"><akn:num>379h–2</akn:num><akn:heading>Reauthorization; reporting requirements</akn:heading><akn:content><akn:p>§ 379h–2. Reauthorization; reporting requirements(a) Performance report(1) In generalNot later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning—(A) the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 101(b) 11 See References in Text note below. of the Prescription Drug User Fee Amendments of 2022 during such fiscal year and the future plans of the Food and Drug Administration for meeting the goals, including the status of the independent assessment described in such letters; and

(B) the progress of the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research in achieving the goals, and future plans for meeting the goals, including, for each review division—(i) the number of original standard new drug applications and biologics license applications filed per fiscal year for each review division;

(ii) the number of original priority new drug applications and biologics license applications filed per fiscal year for each review division;

(iii) the number of standard efficacy supplements filed per fiscal year for each review division;

(iv) the number of priority efficacy supplements filed per fiscal year for each review division;

(v) the number of applications filed for review under accelerated approval per fiscal year for each review division;

(vi) the number of applications filed for review as fast track products per fiscal year for each review division;

(vii) the number of applications filed for orphan-designated products per fiscal year for each review division;

(viii) the number of breakthrough designations for a fiscal year for each review division; and

(ix) the number of investigational new drug applicatio</akn:p></akn:content><akn:subsection eId="subsec_379h_2_a"><akn:num>(a)</akn:num><akn:heading>Performance report</akn:heading><akn:content><akn:p>(a) Performance report</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379h_2_b"><akn:num>(b)</akn:num><akn:heading>Fiscal report</akn:heading><akn:content><akn:p>(b) Fiscal report Not later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379h_2_c"><akn:num>(c)</akn:num><akn:heading>Corrective action report</akn:heading><akn:content><akn:p>(c) Corrective action report For each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit a corrective action report to the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate. The report shall include the following information, as applicable:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379h_2_d"><akn:num>(d)</akn:num><akn:heading>Enhanced communication</akn:heading><akn:content><akn:p>(d) Enhanced communication</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379h_2_e"><akn:num>(e)</akn:num><akn:heading>Public availability</akn:heading><akn:content><akn:p>(e) Public availability The Secretary shall make the reports required under subsections (a) and (b) available to the public on the Internet Web site of the Food and Drug Administration.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379h_2_f"><akn:num>(f)</akn:num><akn:heading>Reauthorization</akn:heading><akn:content><akn:p>(f) Reauthorization</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>